CNS Pharmaceuticals Inc (CNSP)

Welcome to CNS Pharmaceuticals Inc

You are now looking at the newest upcoming pharmaceuticals company. This just launched the IPO on November 8, 2019.

Quote directly from https://cnspharma.com/

Based on human clinical trial data, our lead drug called Berubicin, which was developed at the M.D. Anderson Cancer Center, the largest cancer treatment and research institute in the world, has been shown to get across the blood brain barrier and kill brain tumor cells not reachable by other therapies. In other words, Berubicin may become an effective treatment against glioblastoma, the most aggressive type of brain cancer.

This is a huge opportunity to be a supporter of the new drug Berubicin used to help kill brain tumors.

In the results of the first Berubicin clinical trial, 44% of the patients showed a clinical response, with one Durable Complete Response (a demonstrated lack of detectable cancer cells).

Berubicin has shown evidence of improved survival in a patient population that has currently a dismal median survival rate of only 14.6 months from its diagnosis.

Here is a published time line of future events.